Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Ming‐Huang Chen, Usha Malhotra et al.|The Lancet|2023Cited by 1k
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Camillo Porta, Lorenza Rimassa et al.|The Lancet Oncology|2012Cited by 550
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin AnaloguesRodney J. Hicks, Dik J. Kwekkeboom, Eric P. Krenning et al.|Neuroendocrinology|2017Cited by 331
An update on treatment options for pancreatic adenocarcinomaAurélien Lambert, Thierry Conroy, Lilian Schwarz et al.|Therapeutic Advances in Medical Oncology|2019Cited by 211